

## DAFTAR PUSTAKA

- Airy M, Raghavan R, Truong LD, Eknayan G, 2013. Tubulointerstitial nephritis and cancer chemotherapy: Update on a neglected clinical entity. *Nephrology Dialysis Transplantation*, 28:2502–2509. <https://doi.org/10.1093/ndt/gft241>
- Arga M, Oguz A, Pinarli FG, Karadeniz C, Citak EC, Emeksiz HC, et al., 2015. Risk factors for cisplatin-induced long-term nephrotoxicity in pediatric cancer survivors. *Pediatr Int*, 57:406–413. <https://doi.org/10.1111/ped.12542>
- Barton CD, Pizer B, Jones C, Oni L, Pirmohamed M, Hawcutt DB, 2018. Identifying cisplatin-induced kidney damage in paediatric oncology patients. *Pediatr. Nephrol.* <https://doi.org/10.1007/s00467-017-3765-6>
- Basu A, Krishnamurthy S, 2010. Cellular responses to cisplatin-induced DNA damage. *J Nucleic Acids.* <https://doi.org/10.4061/2010/201367>
- Berardi R, Torniai M, Lenci E, Pecci F, Morgese F, Rinaldi S, 2019. Electrolyte disorders in cancer patients: a systematic review. *J Cancer Metastasis Treat*, 2019. <https://doi.org/10.20517/2394-4722.2019.008>
- Bhandari R, Scott E, Yeh MY, Wong K, Rushing T, Huh W, et al., 2020. Association of body mass index with toxicity and survival in pediatric patients treated with cisplatin-containing regimens. *Pediatr Hematol Oncol*, 38:239–250. <https://doi.org/10.1080/08880018.2020.1842952>
- Bhat ZY, Cadnapaphornchai P, Ginsburg K, Sivagnanam M, Chopra S, Treadway CK, et al., 2015. Understanding the risk factors and long-term consequences of cisplatin-associated acute kidney injury: An observational cohort study. *PLoS One*, 10:1–9. <https://doi.org/10.1371/journal.pone.0142225>
- Brinksma A, Huizinga G, Sulkers E, Kamps W, Roodbol P, Tissing W, 2012. Malnutrition in childhood cancer patients: A review on its prevalence and possible causes. *Crit Rev Oncol Hematol*, 83:249–275. <https://doi.org/10.1016/j.critrevonc.2011.12.003>
- Dasari S, Bernard Tchounwou P, 2014. Cisplatin in cancer therapy: Molecular mechanisms of action. *Eur J Pharmacol.* <https://doi.org/10.1016/j.ejphar.2014.07.025>
- Desiani E, Suharjono S, Yulistiani Y, Susilo DH, 2017. Analysis of NaCl-Mannitol Hydration on Renal Function of Head and Neck Cancer Patients Receiving High-Dose Cisplatin Chemotherapy Combination. *Folio Medica Indones*, 53:64. <https://doi.org/10.20473/fmi.v53i1.5492>
- Erdlenbruch B, Nier M, Kern W, Hiddemann W, Pekrun A, Lakomek M, 2001. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients. *Eur J Clin Pharmacol.* <https://doi.org/10.1007/s002280100319>
- Fan F, Jia J, Li J, Huo Y, Zhang Y, 2017. White blood cell count predicts the odds of kidney function decline in a Chinese community-based population. *BMC Nephrol.* <https://doi.org/10.1186/s12882-017-0608-4>
- Gameiro J, Lopes JA, 2019. Complete blood count in acute kidney injury prediction: a narrative review. *Ann Intensive Care*, 9. <https://doi.org/10.1186/s13613-019-0561-4>

- Gaspari F, Cravedi P, Mandalà M, Perico N, De Leon FR, Stucchi N, et al., 2010. Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: A pilot prospective case-control study. *Nephron Clin Pract*, 115. <https://doi.org/10.1159/000312879>
- Ghosh S, 2019. Cisplatin: The first metal based anticancer drug. *Bioorg Chem*, 88:102925. <https://doi.org/10.1016/j.bioorg.2019.102925>
- Han SS, Ahn SY, Ryu J, Baek SH, Kim K Il, Chin HJ, et al., 2014. U-shape relationship of white blood cells with acute kidney injury and mortality in critically ill patients. *Tohoku J. Exp. Med*, 232:177–185. <https://doi.org/10.1620/tjem.232.177>
- Howard R, Kanetsky PA, Egan KM, 2019. Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer. *Sci Rep*. <https://doi.org/10.1038/s41598-019-56218-z>
- Hsieh P, Yamane K, 2008. DNA mismatch repair: Molecular mechanism, cancer, and ageing. *Mech Ageing Dev*, 129:391–407. <https://doi.org/10.1016/j.mad.2008.02.012>
- Israels T, Afungchwi GM, Chagaluka G, Hesseling P, Kouya F, Paintsil V, et al., 2021. Early death and treatment-related mortality: A report from SUCCOUR - Supportive Care for Children with Cancer in Africa. *Pediatr Blood Cancer*. <https://doi.org/10.1002/pbc.29230>
- Joffe L, Dwyer S, Glade Bender JL, Frazier AL, Ladas EJ, 2019. Nutritional status and clinical outcomes in pediatric patients with solid tumors: A systematic review of the literature. *Semin Oncol*, 46:48–56. <https://doi.org/10.1053/j.seminoncol.2018.11.005>
- Kalantar-Zadeh K, Streja E, Miller JE, Nissenson AR, 2009. Intravenous Iron Versus Erythropoiesis-Stimulating Agents: Friends or Foes in Treating Chronic Kidney Disease Anemia? *Adv Chronic Kidney Dis*, 16:143–151. <https://doi.org/10.1053/j.ackd.2008.12.008>
- Kamileri I, Karakasilioti I, Garinis GA, 2012. Nucleotide excision repair: New tricks with old bricks. *Trends Genet*. <https://doi.org/10.1016/j.tig.2012.06.004>
- Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group, 2021. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. *Kidney Int*, 2:S1–S276.
- Kooijmans E, Bokenkamp A, Tjahjadi N, Tettero J, van Dulmen-den Broeder E, van der Pal H, et al., 2019. Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer (review). *Cochrane Database Syst Rev*. <https://doi.org/10.1002/14651858.CD008944.pub3>. [www.cochranelibrary.com](http://www.cochranelibrary.com)
- Lee SA, Noel S, Sadasivam M, Hamad ARA, Rabb H, 2017. Role of Immune Cells in Acute Kidney Injury and Repair. *Nephron*. <https://doi.org/10.1159/000477181>
- Lee Y, Ryu J, Kang MW, Seo KH, Kim J, Suh J, et al., 2021. Machine learning-based prediction of acute kidney injury after nephrectomy in patients with

- renal cell carcinoma. *Sci Rep*, 11:1–8. <https://doi.org/10.1038/s41598-021-95019-1>
- Lehane D, Winston A, Gray R, Daskal Y, 1979. The effect of diuretic pre-treatment on clinical, morphological and ultrastructural cis-platinum induced nephrotoxicity. *Int J Radiat Oncol Biol Phys*, 5:1393–1399. [https://doi.org/10.1016/0360-3016\(79\)90677-1](https://doi.org/10.1016/0360-3016(79)90677-1)
- Li GM, 2008. Mechanisms and functions of DNA mismatch repair. *Cell Res*. <https://doi.org/10.1038/cr.2007.115>
- Macciò A, Madeddu C, Gramignano G, Mulas C, Tanca L, Cherchi MC, et al., 2015. The role of inflammation, Iron, And nutritional status in cancer-related anemia: Results of a large, Prospective, Observational study. *Haematologica*. <https://doi.org/10.3324/haematol.2014.112813>
- Madeddu C, Sanna E, Oppi S, Macciò A, 2021. Experimental Drugs for Chemotherapy- and Cancer- Related Anemia. *J. Exp. Pharmacol* 593–611.
- McMahon KR, Harel-Sterling M, Pizzi M, Huynh L, Hessey E, Zappitelli M, 2018. Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study. *Pediatric Nephrology*. <https://doi.org/10.1007/s00467-018-3976-5>
- McMahon KR, Rassekh SR, Schultz KR, Blydt-Hansen T, Cuvelier GDE, Mammen C, et al., 2020. Epidemiologic Characteristics of Acute Kidney Injury During Cisplatin Infusions in Children Treated for Cancer. *JAMA Netw Open*, 3:e203639. <https://doi.org/10.1001/jamanetworkopen.2020.3639>
- McSweeney KR, Gadanec LK, Qaradakh T, Ali BA, Zulli A, Apostolopoulos V, 2021. Mechanisms of cisplatin-induced acute kidney injury: Pathological mechanisms, pharmacological interventions, and genetic mitigations. *Cancers (Basel)*. <https://doi.org/10.3390/cancers13071572>
- Miller RP, Tadagavadi RK, Ramesh G, Reeves WB, 2010. Mechanisms of cisplatin nephrotoxicity. *Toxins (Basel)*, 2:2490–2518.
- Miyoshi T, Uoi M, Omura F, Tsumagari K, Maesaki S, Yokota C, 2021. Risk Factors for Cisplatin-Induced Nephrotoxicity: A Multicenter Retrospective Study. *Oncology (Switzerland)*, 99:105–113. <https://doi.org/10.1159/000510384>
- Mizuno T, Ishikawa K, Sato W, Koike T, Kushida M, Miyagawa Y, et al., 2013. The risk factors of severe acute kidney injury induced by cisplatin. *Oncology (Switzerland)*, 85:364–369. <https://doi.org/10.1159/000356587>
- Mohammadi AS, Li X, Ewing AG, 2018. Mass Spectrometry Imaging Suggests That Cisplatin Affects Exocytotic Release by Alteration of Cell Membrane Lipids. *Anal Chem*, 90:8509–8516. <https://doi.org/10.1021/acs.analchem.8b01395>
- Moreno-Gordaliza E, Marazuela MD, Pastor Ó, Lázaro A, Gómez-Gómez MM, 2021. Lipidomics reveals cisplatin-induced renal lipid alterations during acute kidney injury and their attenuation by cilastatin. *Int J Mol Sci*, 22. <https://doi.org/10.3390/ijms222212521>
- Motawi TK, Abd-Elgawad HM, Shahin NN, 2013. Effect of protein malnutrition on the metabolism and toxicity of cisplatin, 5-fluorouracil and mitomycin C

- in rat stomach. *Food Chem. Toxicol*, 56:467–482.  
<https://doi.org/10.1016/j.fct.2013.02.042>
- Motwani SS, McMahon GM, Humphreys BD, Partridge AH, Waikar SS, Curhan GC, 2018. Development and validation of a risk prediction model for acute kidney injury after the first course of cisplatin. *Journal of Clinical Oncology*, 36:682–688. <https://doi.org/10.1200/JCO.2017.75.7161>
- Nayak A, McDowell DT, Kellie SJ, Karpelowsky J, 2017. Elevated Preoperative Neutrophil–Lymphocyte Ratio is Predictive of a Poorer Prognosis for Pediatric Patients with Solid Tumors. *Ann Surg Oncol*.  
<https://doi.org/10.1245/s10434-017-6006-0>
- Oda H, Mizuno T, Ikejiri M, Nakamura M, Tsunoda A, Ishihara M, et al., 2020. Risk factors for cisplatin-induced acute kidney injury: A pilot study on the usefulness of genetic variants for predicting nephrotoxicity in clinical practice. *Mol Clin Oncol*, 13:1–6. <https://doi.org/10.3892/mco.2020.2127>
- Oun R, Moussa YE, Wheate NJ, 2018. The side effects of platinum-based chemotherapy drugs: A review for chemists. *Dalton Trans*, 47:6645–6653.  
<https://doi.org/10.1039/c8dt00838h>
- Pabla N, Dong Z, 2008. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. *Kidney Int*. <https://doi.org/10.1038/sj.ki.5002786>
- Park PG, Hong CR, Kang E, Park M, Lee H, Kang HJ, et al., 2019. Acute Kidney Injury in Pediatric Cancer Patients. *Journal of Pediatrics*, 208:243-250.e3.  
<https://doi.org/10.1016/j.jpeds.2018.12.023>
- Perazella MA, 2012. Onco-nephrology: Renal toxicities of chemotherapeutic agents. *CJASN*, 7:1713–1721. <https://doi.org/10.2215/CJN.02780312>
- Pole JD, Gibson P, Ethier MC, Lazor T, Johnston DL, Portwine C, et al., 2017. Evaluation of treatment-related mortality among paediatric cancer deaths: A population based analysis. *Br J Cancer*, 116:540–545.  
<https://doi.org/10.1038/bjc.2016.443>
- Prasaja Y, Sutandyo N, Andrajati R, 2015. Incidence of cisplatin-induced nephrotoxicity and associated factors among cancer patients in Indonesia. *Asian Pac. J. Cancer Prev*, 16:1117–1122.  
<https://doi.org/10.7314/APJCP.2015.16.3.1117>
- Puisset F, Bigay-Game L, Paludetto MN, Martel A, Perriat S, Rabeau A, et al., 2019. Safety of oral hydration after cisplatin infusion in an outpatient lung cancer unit. *Support Care Cancer*, 27:1679–1686.  
<https://doi.org/10.1007/s00520-018-4415-7>
- Purwanto I, Azizah NF, Ambarwati DD, 2022. Protokol yang Menggunakan Cisplatin atau Carboplatin. Yogyakarta: 2022.
- Rivel T, Ramseyer C, Yesylevskyy S, 2019. The asymmetry of plasma membranes and their cholesterol content influence the uptake of cisplatin. *Sci Rep*, 9. <https://doi.org/10.1038/s41598-019-41903-w>
- Robinson D, Schulz G, Langley R, Donze K, Winchester K, Rodgers C, 2014. Evidence-Based Practice Recommendations for Hydration in Children and Adolescents With Cancer Receiving Intravenous Cyclophosphamide. *J Pediatr Oncol Nurs*, 31:191–199. <https://doi.org/10.1177/1043454214532024>

- Rosner MH, Jhaveri KD, McMahon BA, Perazella MA, 2021. Onconeurology: The intersections between the kidney and cancer. *CA Cancer J Clin*. <https://doi.org/10.3322/caac.21636>
- Rossi L, Santoni M, Crabb SJ, Scarpi E, Burattini L, Chau C, et al., 2015. High Neutrophil-to-lymphocyte Ratio Persistent During First-line Chemotherapy Predicts Poor Clinical Outcome in Patients with Advanced Urothelial Cancer. *Ann Surg Oncol*. <https://doi.org/10.1245/s10434-014-4097-4>
- Ruggiero A, Ariano A, Triarico S, Capozza MA, Romano A, Maurizi P, et al., 2021. Cisplatin-induced nephrotoxicity in children: what is the best protective strategy? *JOPP*, 27:180–186. <https://doi.org/10.1177/1078155220961550>
- Ruggiero A, Trombatore G, Triarico S, Capozza MA, Coccia P, Attina G, et al., 2019. Cisplatin toxicity in children with malignancy. *Biomed. Pharmacol. J*, 12:1603–1611. <https://doi.org/10.13005/bpj/1791>
- Shema-Didi L, Ore L, Geron R, Kristal B, 2010. Is anemia at hospital admission associated with in-hospital acute kidney injury occurrence? *Nephron Clin Pract*, 115. <https://doi.org/10.1159/000312881>
- Skinner R, Pearson ADJ, English MW, Price L, Wyllie RA, Coulthard MG, et al., 1998. Cisplatin dose rate as a risk factor for nephrotoxicity in children. *Br J Cancer*, 77:1677–1682. <https://doi.org/10.1038/bjc.1998.276>
- Sprangers B, Cosmai L, Porta C, 2020. Conventional chemotherapy. In: Finkel KW, Perazella MA, Cohen EP, Editors. *JON*. Missouri: Elsevier; 2020. pp. 127–153.
- Suwananta IM, Ariawati K, Widnyana AANKP, Lastariana KAY, 2021. Prevalence and Characteristic of Pediatric Solid Tumor in Sanglah Hospital Bali. *Int. J. Health Sci*, 4:322–332.
- U.S. Department of Health and Human Services, 2017. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 [WWW Document]. Cancer Therapy Evaluation Program. <https://doi.org/10.1039/DT9930001947>
- Van Der Vorst MJDL, Neefjes ECW, Toffoli EC, Oosterling-Jansen JEW, Vergeer MR, Leemans CR, et al., 2019. Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin. *BMC Cancer*. <https://doi.org/10.1186/s12885-019-6233-9>
- Vasquez L, León E, Beltran B, Maza I, Oscanoa M, Geronimo J, 2017. Pretreatment Neutrophil-to-Lymphocyte Ratio and Lymphocyte Recovery: Independent Prognostic Factors for Survival in Pediatric Sarcomas. *J Pediatr Hematol Oncol*, 39:538–546. <https://doi.org/10.1097/MPH.0000000000000911>
- Von Allmen D, 2020. Principles of Adjuvant Therapy in Childhood Cancer. In: Holcomb III GW, Murphy JP, Peter SDS, Gatti JM, Editors. *Holcomb and ashcraft's pediatric surgery*. Sydney: Elsevier; 2020. pp. 968–985.
- Wang D, Hara R, Singh G, Sancar A, Lippard SJ, 2003. Nucleotide excision repair from site-specifically platinum-modified nucleosomes. *Biochemistry*, 42:6747–6753. <https://doi.org/10.1021/bi034264k>





- Wang D, Lippard SJ, 2005. Cellular processing of platinum anticancer drugs. *Nat Rev Drug Discov*, 4:307–320. <https://doi.org/10.1038/nrd1691>
- Wellstein A, Giaccone G, Atkins MB, Sausville EA, 2018. Pharmacotherapy of Neoplastic Disease: Cytotoxic Drugs. In: Brunton LL, Hilal-Dandan R, Knollmann BC, Editors. *Goodman and Gilman's the pharmacological basis of therapeutics*. Singapore: McGraw-Hill; 2018. pp. 1176–1177. <https://doi.org/10.2307/3757079>
- World Health Organization, 2020. Framework: WHO Global Initiative for Childhood Cancer [WWW Document]. CureAll framework: WHO global initiative for childhood cancer: increasing access, advancing quality, saving lives. <https://doi.org/10.1016/j.phoj.2020.06.005>
- Yoshitomi R, Nakayama M, Sakoh T, Fukui A, Katafuchi E, Seki M, et al., 2019. High neutrophil/lymphocyte ratio is associated with poor renal outcomes in Japanese patients with chronic kidney disease. *Ren Fail*, 41:238–243. <https://doi.org/10.1080/0886022X.2019.1595645>
- Zazuli Z, Kos R, Veltman JD, Uytendinck W, Longo C, Baas P, et al., 2020. Comparison of Myelotoxicity and Nephrotoxicity Between Daily Low-Dose Cisplatin With Concurrent Radiation and Cyclic High-Dose Cisplatin in Non-Small Cell Lung Cancer Patients. *Front Pharmacol*, 11:1–12. <https://doi.org/10.3389/fphar.2020.00975>
- Zazuli Z, Op 't Hoog CJP, Vijverberg SJH, Masereeuw R, Rassekh SR, Medeiros M, et al., 2023. Cisplatin-induced nephrotoxicity in childhood cancer: comparison between two countries. *Pediatr. Nephrol*, 38:593–604. <https://doi.org/10.1007/s00467-022-05632-z>